Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.